This is a promotional roadshow of meetings organised and funded by Angelini Pharma UK-I, and is intended for UK healthcare professionals only.
Hear how US and UK experts are using ONTOZRY® for the treatment of drug-resistant focal-onset seizures to help their epilepsy patients reach their goals.
ONTOZRY® is indicated for the adjunctive treatment of focal-onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite treatment with at least 2 anti-epileptic medicinal products.1
1. ONTOZRY® Summary of Product Characteristics.
UK12063P | May 2022